Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Aldurazyme | Laronidase | Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete |